Clovis planning follow-on

Clovis Oncology Inc. (NASDAQ:CLVS) proposed to raise $75 million in a follow-on underwritten by JPMorgan; Credit Suisse; and Leerink. Clovis' CO-101 is in a pivotal Phase II trial for first-line treat...